MedTrace Logo

Detection of Tumor DNA in Blood Samples From Patients With Early Stage Cancer and "Healthy Controls"

NCT03071809 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2019-08-14

No results posted yet for this study

Summary

The aim of this study is to employ genomic detection methodologies to measure the relative amount of tumor-derived nucleic acids in the blood of patients diagnosed with an early stage solid tumor who are either commencing, currently undergoing or have completed treatment. This approach will allow the investigators to develop a quantitative measure of therapy efficacy via the counting of the relative changes in tumor molecules over the course of treatment.

Conditions

  • Neoplasms, Non-hematologic - Stage I-III

Sponsors & Collaborators

  • Lexent Bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Haluk Tezcan, MD · Lexent Bio

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-06-30
Primary Completion
2019-03-15
Completion
2019-03-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03071809 on ClinicalTrials.gov